Protara Therapeutics Inc (NASDAQ:TARA) does about 2.02M shares in volume on a normal day but saw 2303835 shares change hands in the recent trading day. The company now has a market cap of 135.08M USD. Its current market price is $6.67, marking an increase of 12.86% compared to the previous close of $5.91. The 52 week high reached by this stock is $10.48 whilst the lowest price level in 52 weeks is $1.37.
Protara Therapeutics Inc (TARA) has a 20-day trading average at $3.18 and the current price is -36.35% off the 52-week high compared with 386.86% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.50 and its 200-day simple moving average is $2.68. If we look at the stock’s price movements over the week, volatility stands at 35.62%, which decreases to 15.18% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 86.49 to suggest the stock is overbought.
The consensus objective for the share price is $26.40, suggesting that the stock has a potential upside of 74.73% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 10, 2023 when Guggenheim resumed the stock to “Buy” and issued a price target of $22. Oppenheimer initiated its price target at $43.
The current price level is 109.75%, 166.59%, and 148.92% away from its SMA20, SMA50, and SMA200 respectively, with the TARA price moving below the 50-day SMA on current market day. Protara Therapeutics Inc (TARA) stock is up 163.64% over the week and 162.60% over the past month. Its price is 255.71% year-to-date and 386.86% over the past year.
To reach the target analysts have set, the stock logically needs to grow 74.73 percent from here.
The company has a return on investment of -49.21% and return on equity of -52.97%. The beta has a value of 1.72. Price to book ratio is 1.68.
